In the venture capital circle for a long time, it is more and more important to feel that investment institutions are very important. Sometimes it is the life and death of a company, and sometimes it may be the future of a technology. Therefore, sometimes we especially want to know the judgment of an investment institution on the track and trend.
I have also tried to understand this so-called "judgment" in the past. Frankly speaking, the effect is not good. Many investors are willing to exchange views and thoughts with the industry very frankly, but they are often not willing to implement them in a certain direction or direction in a special way.
Of course, there may be smoke bombs sometimes. My colleague told me that sometimes I ask people about the trend. It is very likely that they have invested in a company in the past. They will tell you what direction they are optimistic about, which is more conducive to finding someone to take over. It sounds very interesting. But from another point of view, since people have already invested in the company in that direction, chances are that they are really optimistic.
So, I refer to the various lists that I just issued at the end of last year. I really found 15 investment institutions and pulled out the investment projects they disclosed in 2016 from the database. There must be some omissions, but I can see it. A glance at the past, angels, A's majority, B's occasional, rare after C.
From a specific perspective, in addition to very few projects, the O2O model has almost disappeared. Basic medical and precision medical projects account for the majority. From this point of view, the projects invested by investment institutions are generally in line with the overall trend of 2016. One is the sinking of medical resources and the market in the context of grading diagnosis and treatment. One is the rise of precision medicine driven by the sudden drop in the cost of genetic sequencing . According to the current trend, these two hot spots are likely to continue in 2017.
Another question is whether the entrepreneurship of Chinese medicine will break out. In 2015, there was a wave of Chinese medicine that broke out and it did not last. There are very few projects in 2016. There are large project financing disclosures like Jun He Tang, but Feng Mao Ling. However, 2016 has indeed introduced many policies to encourage Chinese medicine, but the problems of Chinese medicine itself cannot be ignored.
Rao Yi approved Chinese medicine injections a few days ago: There are now a number of Chinese medicine factories that want to sell Chinese medicine injections to the whole country. This not only bypasses the scientific test required by Western medicine, but also does not allow the Chinese medicine to promote it in a large amount. This is a businessman. Practice, this is pseudoscience, it is for the purpose of murder. The scientific and standardized contradictions faced by Chinese medicine have always been a problem.
In addition, the variables that may exist in 2017 are very, very much.
China Veterinary Raw,Low Price Ampicillin supplier & manufacturer, offer low price, high quality Cas 7177-48-2 Ampicillin,Ampicillin Powder, etc.
Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.
For customer`s needs, OEM service is also acceptable. If you have a good idea in new product production but lack of laboratory device and human resource, we are glad to solve this problem for you. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.
Veterinary Raw,Amprolium And Decoquinate,Abamectin Active Ingredient,Bifenthrin Active Ingredient
Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikangbio.com